DOSEGUY

Pyrilutamide

weak data

Also seen as: KX-826, KX826

The Dose Guy’s verdict
Sep 1, 2026
1 source

The most interesting topical antiandrogen on the shelf right now, and the one in active clinical development for hair loss. Pyrilutamide is aiming to block DHT at the scalp without a systemic hormonal hit, and Kintor Pharma is doing the human work to prove it. The catch: the published data is still thin and the trial signals so far are mixed. Interest, not a verdict.

Would I take it?Not yet, but I'm watching.

What it is

A topical androgen receptor antagonist out of Kintor Pharma, designed to sit on the scalp and block DHT right where it shrinks your follicles. The idea is the same one behind RU58841: block DHT at the follicle instead of cutting production body-wide the way finasteride does. Pyrilutamide’s edge over the older research chemicals is that it is in a formal drug development program, with real trials, real regulatory filings, and a company that has to show its data. That does not mean it works yet. It means the answer will come from data, not guessing.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published literature is thin for a compound this far along:

In a hair-growth mouse model, 0.5% pyrilutamide showed efficacy comparable to a newer soft-drug candidate at the same concentration.J Med Chem 2026 · in vitro + mouse model
No randomized human trial abstract reporting participant counts or numerical hair-growth outcomes appears in PubMed. The clinical data that exists lives in Chinese regulatory filings and conference presentations.as of Aug 2026
No human pharmacokinetic study reporting systemic exposure, blood concentrations, or clearance has been published.as of Aug 2026

Realistic protocols

The honest advice is to wait and run the proven pair, finasteride and minoxidil, while you do. Pyrilutamide is interesting precisely because trials are running, and those trials will either deliver the data that justifies a real protocol or they won’t. Running it now means paying research-chemical prices for a compound whose dose-response curve nobody has published.

People running it ahead of approval are sourcing raw powder and mixing it into a topical solution at 0.5%, the concentration from the mouse work and the number the community has landed on. Once daily to the scalp, usually at night. Let it dry before bed or before layering other topicals. If you are also running minoxidil, apply them separately and give each one time to absorb. Source matters more than usual: a third-party COA is the floor, not the ceiling.

Concentration0.5%From the mouse work. Community standard, not a human-trial figure.
FrequencyOnce dailyApplied to scalp at night. Community convention, not trial-derived.
Minimum run3–6 monthsHair cycles are slow. Judge by comparison photos, not the mirror.

Side effects

No human adverse-event data has been published, so this is the class profile plus anecdote:

anecdotalScalp irritation and dryness from the vehicle, the universal complaint with daily alcohol-based topicals.
anecdotalEarly shedding in the first weeks, consistent with a topical antiandrogen resetting follicle cycles.
unknownSystemic absorption is unmeasured in any published study. The point of a topical antiandrogen is staying local, but nobody has confirmed pyrilutamide does.

Where to buy

RUO.bio–
$68 / 150mg vial$0.45/mg
✓ verified Sep 12
Read review →
Visit →

Prices move. Links are affiliate links; they never change a ranking, and scores are set before the deal exists.